For all media enquiries please contact Katarina Janerud, 
Communications Manager: 

Tel: +46 8 440 50 50 
Direct: +46 8 440 50 69 
Mobile: +46 709 69 69 99
Fax. +46 8 611 79 98 

ConvaTec announces the appointment of Ken Berger to the position of CEO effective March 6, 2012

Feb 21, 2012

David I. Johnson to step down as CEO and resign from Board of Directors

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announces that Ken Berger will assume the position of CEO, ConvaTec, and will be appointed to the ConvaTec Board of Directors.

Berger joins ConvaTec from Thermo Fisher Scientific where he spent the last ten years, most recently as Senior Vice President and Group resident of the Specialty Diagnostics Group, a global $2 billion high-value diagnostics business.  "We are excited to have Ken take over the helm of ConvaTec," said Toni Weitzberg, Chairman of the Board of Directors for ConvaTec.  "His track record of building highly profitable businesses, combined with diverse global experience and a history of building strong leadership teams is well suited to take ConvaTec to the next level of performance excellence."

"I am pleased to work with Nordic Capital and Avista Capital Partners as CEO of ConvaTec," said Berger, "and I look forward to working with the ConvaTec team to realize the incredible potential of this business."

This appointment follows the mutual agreement between David I. Johnson and the ConvaTec Board of Directors that he will step down as CEO, effective March 5, 2012.  "Dave successfully managed the carve-out from Bristol Myers Squibb Co. and created an independent global company with a strong platform for growth." stated Weitzberg, "The Board thanks him for his service in leading ConvaTec over the past six years, and for his dedication to the Company for over twelve years."

"I am proud to leave this fine organization with a strengthened financial foundation, renewed growth momentum; and of course, a continued commitment to the company mission." said Johnson.  "I am confident that the entire organization is ready to take ConvaTec to even greater heights."

Over the next sixty days, Johnson will work with the Board and his successor to ensure an orderly transition of leadership.

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas - Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices - ConvaTec products support healthcare professionals from the hospital to the community health setting. For more information, please visit

About Nordic Capital Private Equity Funds

Since the start in 1989, Nordic Capital Private Equity Funds have invested in large and medium sized companies, primarily in Northern Europe. Through committed ownership and by targeting strategic development and operational improvements, Nordic Capital creates value in its investments. The funds invest in companies in Northern Europe and in selected investment opportunities internationally. They are based in Jersey, Channel Islands, and are advised by the NC Advisory companies in Sweden, Denmark, Finland, Norway, Germany and the UK. Additional information about Nordic Capital is available through its corporate website,

Back to news listings >